EP3562447A1 - Tampon oculaire et procédé de chauffage d'une zone péri-oculaire - Google Patents
Tampon oculaire et procédé de chauffage d'une zone péri-oculaireInfo
- Publication number
- EP3562447A1 EP3562447A1 EP17829039.1A EP17829039A EP3562447A1 EP 3562447 A1 EP3562447 A1 EP 3562447A1 EP 17829039 A EP17829039 A EP 17829039A EP 3562447 A1 EP3562447 A1 EP 3562447A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pad
- ocular
- pad according
- gel material
- anyone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000010792 warming Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 12
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000000499 gel Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FWQHNLCNFPYBCA-UHFFFAOYSA-N fluoran Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C11OC(=O)C2=CC=CC=C21 FWQHNLCNFPYBCA-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000011253 protective coating Substances 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 210000000744 eyelid Anatomy 0.000 description 16
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 13
- -1 N-ethyl-p- toluidino Chemical group 0.000 description 12
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 8
- 206010013774 Dry eye Diseases 0.000 description 8
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 5
- 210000004175 meibomian gland Anatomy 0.000 description 5
- 206010061876 Obstruction Diseases 0.000 description 4
- MQXNNWDXHFBFEB-UHFFFAOYSA-N 2,2-bis(2-hydroxyphenyl)propane Chemical compound C=1C=CC=C(O)C=1C(C)(C)C1=CC=CC=C1O MQXNNWDXHFBFEB-UHFFFAOYSA-N 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 2
- 241001608562 Chalazion Species 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IMHDGJOMLMDPJN-UHFFFAOYSA-N biphenyl-2,2'-diol Chemical group OC1=CC=CC=C1C1=CC=CC=C1O IMHDGJOMLMDPJN-UHFFFAOYSA-N 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- JJXVDRYFBGDXOU-UHFFFAOYSA-N dimethyl 4-hydroxybenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=C(O)C=C1C(=O)OC JJXVDRYFBGDXOU-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000021792 sore eyes Diseases 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HUOKHAMXPNSWBJ-UHFFFAOYSA-N 2'-chloro-6'-(diethylamino)-3'-methylspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(C)C=C1OC1=CC(N(CC)CC)=CC=C21 HUOKHAMXPNSWBJ-UHFFFAOYSA-N 0.000 description 1
- GSCLSACFHWKTQU-UHFFFAOYSA-N 2'-chloro-6'-(diethylamino)spiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=CC=C1OC1=CC(N(CC)CC)=CC=C21 GSCLSACFHWKTQU-UHFFFAOYSA-N 0.000 description 1
- YMTYZTXUZLQUSF-UHFFFAOYSA-N 3,3'-Dimethylbisphenol A Chemical compound C1=C(O)C(C)=CC(C(C)(C)C=2C=C(C)C(O)=CC=2)=C1 YMTYZTXUZLQUSF-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- BOTKTAZUSYVSFF-UHFFFAOYSA-N 4-(2,4,4-trimethylpentan-2-yl)benzene-1,2-diol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(O)=C1 BOTKTAZUSYVSFF-UHFFFAOYSA-N 0.000 description 1
- NZGQHKSLKRFZFL-UHFFFAOYSA-N 4-(4-hydroxyphenoxy)phenol Chemical compound C1=CC(O)=CC=C1OC1=CC=C(O)C=C1 NZGQHKSLKRFZFL-UHFFFAOYSA-N 0.000 description 1
- ZTILAOCGFRDHBH-UHFFFAOYSA-N 4-(4-propan-2-yloxyphenyl)sulfonylphenol Chemical compound C1=CC(OC(C)C)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 ZTILAOCGFRDHBH-UHFFFAOYSA-N 0.000 description 1
- ODJUOZPKKHIEOZ-UHFFFAOYSA-N 4-[2-(4-hydroxy-3,5-dimethylphenyl)propan-2-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C(C)(C)C=2C=C(C)C(O)=C(C)C=2)=C1 ODJUOZPKKHIEOZ-UHFFFAOYSA-N 0.000 description 1
- XHQYAMKBTLODDV-UHFFFAOYSA-N 4-[2-(4-hydroxyphenyl)heptan-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(C)(CCCCC)C1=CC=C(O)C=C1 XHQYAMKBTLODDV-UHFFFAOYSA-N 0.000 description 1
- PRWJPWSKLXYEPD-UHFFFAOYSA-N 4-[4,4-bis(5-tert-butyl-4-hydroxy-2-methylphenyl)butan-2-yl]-2-tert-butyl-5-methylphenol Chemical compound C=1C(C(C)(C)C)=C(O)C=C(C)C=1C(C)CC(C=1C(=CC(O)=C(C=1)C(C)(C)C)C)C1=CC(C(C)(C)C)=C(O)C=C1C PRWJPWSKLXYEPD-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- NTDQQZYCCIDJRK-UHFFFAOYSA-N 4-octylphenol Chemical compound CCCCCCCCC1=CC=C(O)C=C1 NTDQQZYCCIDJRK-UHFFFAOYSA-N 0.000 description 1
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SDDLEVPIDBLVHC-UHFFFAOYSA-N Bisphenol Z Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)CCCCC1 SDDLEVPIDBLVHC-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- KYPYTERUKNKOLP-UHFFFAOYSA-N Tetrachlorobisphenol A Chemical compound C=1C(Cl)=C(O)C(Cl)=CC=1C(C)(C)C1=CC(Cl)=C(O)C(Cl)=C1 KYPYTERUKNKOLP-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000012963 UV stabilizer Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000013605 boiled eggs Nutrition 0.000 description 1
- RFAHZZDUNWEBLG-UHFFFAOYSA-N butyl 2,2-bis(4-hydroxyphenyl)acetate Chemical compound C=1C=C(O)C=CC=1C(C(=O)OCCCC)C1=CC=C(O)C=C1 RFAHZZDUNWEBLG-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- LXZWFDUCAUBLCD-UHFFFAOYSA-N n-fluoro-2,4-dimethylaniline Chemical compound CC1=CC=C(NF)C(C)=C1 LXZWFDUCAUBLCD-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical group 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0002—Head or parts thereof
- A61F2007/0004—Eyes or part of the face surrounding the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0203—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor
- A61F2007/0215—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor containing liquids other than water
- A61F2007/0219—Gels
Definitions
- the present invention relates to an ocular pad comprising a pocket containing a gel material which reversibly changes color when heated above a threshold temperature. Said pad is particularly suitable for warming a periocular area.
- MGD Meibomian Gland Dysfunction
- DE dry eye
- MGD meibomian Gland Dysfunction
- the MGD is a chronic abnormality of the meibomian glands (MGs) . It may cause eye discomfort and affect tear film stability which leads to poorer visual function, faster tear evaporation and ocular surface damage. MGD is thought to be a major cause of dry eye that affects 46.2-69.3% Asians and 3.5-19.9% Caucasians .
- Meibomian glands are large sebaceous glands that are located as separate gland strands in parallel arrangement within the tarsal plates of the eyelids. Their oily product, meibum, is secreted via a holocrine mechanism during which meibocytes are transformed into the meibum. Following production in the gland acini, meibum is transported through the ductal system via the connecting duct and the central duct towards the orifice at the free eyelid margin close to the inner eyelid border. Meibum is a complex mixture of various lipids and minor protein components as well as other components of the meibocytes, which form a clear liquid at body temperature.
- meibum moves from the posterior eyelid margin reservoir onto the tear meniscus and is pulled as a thin layer onto the pre-ocular tear film every time the eyelid opens. During closure of the eyelid, it is compressed and a small part is continuously renewed. Meibum also has a barrier function against the spillage of tears over the inner border of the eyelid and against the entry of skin lipids (sebum) from the free eyelid margin.
- obstructive meibomian gland dysfunction is a common source of complaint among patients with dry eye syndrome and its prevalence increases with age.
- the main clinical consequence of obstructive MGD is evaporative DE syndrome.
- chronic obstruction of the meibomian glands may also result in degeneration of the secretory gland tissue that can lead to a secondary hypo-secretion even if the primary obstruction is later resolved by therapeutic approaches.
- Risk factors in the pathogenesis of obstructive MGD include age, hormonal disturbances and environmental influences (e.g., contact lenses) .
- qualitative alterations in the composition of the meibum may lead to hyper-keratinization of the ductal epithelium and increased viscosity of the meibum.
- the eyelid warming is regarded as the mainstay of the clinical treatment of ocular conditions [see Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, et al . ; "The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction", Invest. Ophthalmol. Vis. Sci. 2011; 52 ( 4 ) : 2050-2064 ] .
- the eyelid warming is reached by different methods, such as: warmed towel or cotton, eyelid warming masks, and other improvised methods of heating, like warmed seeds or even hard boiled eggs.
- heating means known in the art require to be heated before the application on the eyelid.
- the absence of a system which allows to control the temperature may cause failure of the treatment, since the patient can apply on the eyelid a vehicle that he/she subjectively judges warm, but that has not reached the right temperature for efficacy, making the treatment, often cumbersome, totally ineffective.
- Medium term consequence will be that the patient will no longer comply with the warming treatment, having had proof of inefficacy.
- the Applicant has faced the problem to find a heating device suitable for warming a periocular area, allowing the user to know when the device has reached the therapeutic temperature and is consequently ready to be applied on said area in order to alleviate or treat ocular conditions.
- an ocular pad which can be applied on the periocular area and comprises a pocket containing a gel material which reversibly changes color when heated above a threshold temperature. Particularly, when the pad reaches a temperature suitable for the application to the periocular area, particularly a therapeutically effective temperature, reversible color change in the gel material is observed.
- the present invention relates to an ocular pad comprising a pocket containing a gel material which comprises a thermochromic dye which reversibly changes color when heated above a threshold temperature ranging from 40°C to 45°C.
- the pad of the invention when the pad of the invention reaches the suitable temperature under heating, it changes color noticeably, thus allowing the user to have an immediate visual confirmation that the device is ready to be applied, since it has reached a therapeutically effective warm temperature.
- the control of the temperature for example by a thermometer, is not necessary, having as a result a more convenient, quick and user friendly procedure.
- the pad of the present invention allows to standardize the application on the periocular area. Furthermore, the use of the pad is very easy, so that it is suitable for the domestic use. Moreover, the small size of the pad makes it portable.
- Figure 1 shows a schematic view of the pad according to the invention.
- a pad (1) is shown having a pocket (2) made of polymeric material, which contains the gel material.
- the pocket (2) is closed by a rim (3) obtained by hot welding the plastic edges.
- the pad (1) preferably has a flap (4) which is conveniently shaped to allow an easy handling of the pad (1) during heating and during application on the periocular area.
- peripheral area means the whole periocular area or a partial area thereof, such as, for example, the eyelids (upper and/or lower) .
- the thermochromic dye is a thermochromic leuco-dye. More preferably, the thermochromic dye comprises a fluoran-based dye and a developer. Preferably, the weight ratio between the fluoran-based dye and the developer ranges from 30:70 to 70:30, more preferably from 40:60 to 60:40.
- the fluoran-based dye is preferably selected from: 3-diethylamino- 6-methyl- 7,2, 4-xylidinofluoran, 3-dimethylamino-7- methoxyfluoran, 3-diethylamino- 6-methoxyfluoran, 3- diethy1amino-7-methoxyfluoran, 3-diethylamino-7- chlorofluoran, 3-diethylamino- 6-methyl-7-chlorofluoran, 3-diethylamino-6, 7-dimethylfluoran, 3- (N-ethyl-p- toluidino) -7-methylfluoran, 3-diethylamino-7-N-acetyl- N-methylamino ) fluoran, 3-diethylamino-7-N- methylaminofluoran, 3-diethylamino-7- dibenzylaminofluoran, 3-diethylamino-7- (N-methyl-N- benzylaminofluoran,
- the developer is a phenolic compound preferably selected from: isopropylidenediphenol (bisphenol A) , p-octylphenol , p- tert-butylphenol , p-phenylphenol , p- hydroxyacetophenone, alpha-naphthol , beta-naphthol , p- tert-octylcatechol, 2 , 2 ' -dihydroxybiphenyl , l,l-bis(p- hydroxyphenyl ) butane, 2 , 2-bis ( 4-hydroxyphenyl ) heptane, 2 , 2-bis ( 3-methyl-4-hydroxyphenyl ) propane, 2,2- bis (3,5- dimethyl-4-hydroxyphenyl ) propane, 2, 2-bis (3, 5-dichloro- 4-hydroxyphenyl ) propane, bis ( 4-hydroxyphenyl ) sulfone, bis ( 3 , 4-dihydroxypheny
- the color change is reversible.
- the qualitative color change depends on the thermochromic dye used. For example, when the threshold temperature is exceeded, the color of the gel material can change from orange or green to yellow.
- thermochromic dye is in the form of droplets microencapsulated in a protective coating.
- the droplets have preferably an average size from 1 ⁇ to 10 ⁇ .
- Microencapsulation of the thermochromic dye can be obtained according to well known techniques (see e.g. the handbook by A. Kondo and J. Wade van Valkenburg, Eds., Microcapsule Processing and Technology', Marcel Dekker (1979) ) .
- the threshold temperature ranges from
- the pad can be effectively used many times, to make the system economically sustainable.
- the ocular pad is made of a polymeric material, which is flexible and soft so as to improve comfort during use.
- a polymeric material may be selected from a large number of materials, such as polyvinylchloride (PVC) , polyethylene, polypropylene, polyesters, polyamides, and the like.
- PVC polyvinylchloride
- the pocket in the pad may be obtained for instance by peripheral hot welding of two superimposed polymer sheets. The pocket is then filled with the gel material according to well known techniques .
- the gel material preferably comprises a gelling agent, which is preferably selected from carboxymethyl cellulose or a salt thereof, particularly sodium carboxymethyl cellulose, agar powder, sodium polyacrylate, and the like.
- a gelling agent which is preferably selected from carboxymethyl cellulose or a salt thereof, particularly sodium carboxymethyl cellulose, agar powder, sodium polyacrylate, and the like.
- the gel material preferably comprises water. Moreover, it preferably comprises a polyol, more preferably glycerin.
- the gel material preferably may contain further ingredients such as: solvents, fillers, preservatives, UV stabilizers, antioxidants, and the like.
- the present invention relates to a method for warming a periocular area, comprising the following steps:
- the above method is particularly suitable to treat various ocular conditions, such as Meibomian Gland Dysfunction (MGD) , dry eye, chalazion, sore eyes and blepharitis .
- MMD Meibomian Gland Dysfunction
- the pad can be heated by dipping the same into hot water or putting the pad under hot running water.
- the pad can be heated by microwave, preferably for a time ranging from 10 to 15 sec.
- the heating by microwave is carried out at 400-500 watt.
- the pad can be of different shapes, such that allowing a suitable and convenient coverage of the periocular area. Moreover, in order to aid the user during the heating step, the pad is equipped with a flap enabling the patient to hold the pad during heating .
- the pad in order to reach a suitable temperature, is heated for at least 3 minutes with hot water.
- the pad can be of any suitable shape for application on the periocular area, such as substantially circular, oval, squared or lobated shape.
- the dimensions are of course suitable to the intended use.
- the diameter is preferably from 3 to 8 cm, preferably from 4 to 6 cm.
- the pad has a thickness from 0.3 cm to 3 cm, more preferably from 0,5 cm cm to 1,5 cm.
- Example 1 The present invention will now be further illustrated by means of the following examples, which are illustrative only and are not intended to limit in any sense the scope of the invention.
- Example 1 The present invention will now be further illustrated by means of the following examples, which are illustrative only and are not intended to limit in any sense the scope of the invention.
- a pad was made by hot welding two layers of flexible PVC (free from phthalates) so as to form a pocket which was filled with a gel material having the following composition:
- the above leuco-dye was in the form of microcapsules by using melamine formaldehyde resin as protective coating.
- the pad as above was dipped into hot water until a change from green to yellow was observed.
- the pad was cooled to room temperature, thus observing a color change from yellow to green, and then repeatedly heated with hot water and cooled to room temperature for 28 times.
- the pad maintained substantially unaltered the ability to change its color from green to yellow and vice versa.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Thermal Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000131691A IT201600131691A1 (it) | 2016-12-28 | 2016-12-28 | Compressa oculare e metodo per scaldare una regione perioculare. |
PCT/IB2017/058335 WO2018122710A1 (fr) | 2016-12-28 | 2017-12-22 | Tampon oculaire et procédé de chauffage d'une zone péri-oculaire |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3562447A1 true EP3562447A1 (fr) | 2019-11-06 |
Family
ID=58609905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17829039.1A Withdrawn EP3562447A1 (fr) | 2016-12-28 | 2017-12-22 | Tampon oculaire et procédé de chauffage d'une zone péri-oculaire |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3562447A1 (fr) |
IT (1) | IT201600131691A1 (fr) |
MA (1) | MA47161A (fr) |
WO (1) | WO2018122710A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7453219B2 (ja) * | 2018-10-11 | 2024-03-19 | インヒブリックス, インコーポレイテッド | Pd-1単一ドメイン抗体およびその治療用組成物 |
AT524665B1 (de) | 2021-05-25 | 2022-08-15 | Aurox Gmbh | Temperiervorrichtung für Gesichtsauflagepads |
AT525631B1 (de) | 2022-05-04 | 2023-06-15 | Aurox Gmbh | Temperiervorrichtung für Gesichtsauflagepads |
DE202022104070U1 (de) | 2022-07-19 | 2023-10-20 | Aurox Gmbh | Temperiervorrichtung zur dermalen Applikation und thermoelektrische Module |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090149925A1 (en) * | 2007-12-05 | 2009-06-11 | Kimberly-Clark Worldwide, Inc. | Temperature Indicator for Warming Products |
US20110077527A1 (en) * | 2009-09-30 | 2011-03-31 | Yang Seungrim | Self-cooling gel substrate for temperature differentiated imaging |
US9510972B2 (en) * | 2012-01-04 | 2016-12-06 | Sight Sciences, Inc. | Dry eye treatment systems |
-
2016
- 2016-12-28 IT IT102016000131691A patent/IT201600131691A1/it unknown
-
2017
- 2017-12-22 EP EP17829039.1A patent/EP3562447A1/fr not_active Withdrawn
- 2017-12-22 WO PCT/IB2017/058335 patent/WO2018122710A1/fr unknown
- 2017-12-22 MA MA047161A patent/MA47161A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018122710A1 (fr) | 2018-07-05 |
IT201600131691A1 (it) | 2018-06-28 |
MA47161A (fr) | 2019-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018122710A1 (fr) | Tampon oculaire et procédé de chauffage d'une zone péri-oculaire | |
US20200000641A1 (en) | Thermally-conductive, metal-based bandages with hydrogel substrate | |
US4559047A (en) | Heat producing mask and method of use | |
ES2361155T3 (es) | Toallitas para el margen de los párpados que comprenden medios químicos para el ajuste de temperatura. | |
US20190159929A1 (en) | Moist heat delivery therapy device with a multi-layer laminate structure | |
EP1632202B1 (fr) | Dispositif humidifiant pour appliquer sur le visage | |
US20160120693A1 (en) | Eye Care Devices and Methods | |
ES2856892T3 (es) | Compuestos de di-isopropil-fosfinoil-alcano (DAPA) como agentes topicos para el tratamiento de molestias sensoriales | |
US6623517B1 (en) | Eye compress | |
WO2019175111A1 (fr) | Coussin thermique, dispositif réfrigérant, système réfrigérant et procédé pour faire fonctionner un coussin thermique et un dispositif réfrigérant | |
US20200129327A1 (en) | Medical device | |
US20190231598A1 (en) | Phase Change Material For Medical And Cosmetic Applications | |
US8517936B1 (en) | Eyelid lifting device | |
MX2014001193A (es) | Vendajes a base de metal termicamente conductor para ayudar en curaciones medicas y metodos de uso. | |
Breakell et al. | CS gas exposure in a crowded night club: the consequences for an accident and emergency department. | |
US20070023048A1 (en) | Cosmetic facial mask | |
CN205339603U (zh) | 纯蚕丝眼贴 | |
CN208809112U (zh) | 敷贴 | |
CN212439040U (zh) | 防雾护目眼镜 | |
GR1010515B (el) | Πολυστρωματικη συσκευη κρυοθεραπειας | |
TH19536A3 (th) | ผลิตภัณฑ์ดูดซึม | |
TH19536C3 (th) | ผลิตภัณฑ์ดูดซึม | |
TWM507212U (zh) | 片狀式面膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20190618 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220407 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230505 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230623 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231104 |